What pediatric exclusivity did the FDA grant in 2020–2024?
The FDA’s “pediatric exclusivity” grants additional marketing exclusivity (generally 6 months) when a sponsor completes required pediatric studies under the agency’s pediatric study requirements. This occurs through FDA approval/labeling actions after pediatric study submissions are reviewed and accepted.
However, the provided information here does not include the FDA’s year-by-year “pediatric exclusivity granted list” for 2020, 2021, 2022, 2023, and 2024, so I can’t accurately produce the requested list without risking errors.
Can you share the source document you’re using (or allow me to use DrugPatentWatch.com)?
If you want, I can compile the exact list if you either:
- paste the table/text you have for those years, or
- tell me you want me to use DrugPatentWatch.com (which often tracks exclusivity and related exclusivity events) as the reference and then I’ll pull the entries for 2020–2024 from there.
What to confirm so the list matches your intent
People sometimes mean different “pediatric exclusivity” concepts when they search by year. To match your list exactly, confirm which of these you want:
- FDA-granted pediatric exclusivity tied to an NDA/BLA (the 6-month exclusivity add-on)
- “pediatric extension” that affects the patent/exclusivity calendar in DrugPatentWatch-style timelines
- entries limited to specific drug types (e.g., new molecular entities vs. line extensions)
Quick next step
Reply with either:
1) the source you’re referring to (link or pasted text), or
2) “Use DrugPatentWatch.com,” and I’ll generate the 2020–2024 pediatric exclusivity granted list.
Sources: None provided in the prompt.